Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal microbiota transplantation capsules in autistic children with gastrointestinal symptoms
MOH_2019-11-28_008521Phase 2Not yet recruiting
- Sponsor
- ד"ר אילן יונגסטר
- Start
- Jul 2019
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allogeneic fecal microbiota in gastrointestinal conditions and Autism Spectrum Disorder (ASD) (2 arms), sponsored by ד"ר אילן יונגסטר. Primary endpoint: Gastrointestinal symptom efficacy after 3 weeks. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
gastrointestinal conditionsAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on MOH_2019-11-28_008521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-11-28_008521.